Literature DB >> 31509430

Rifaximin prevents ethanol-induced liver injury in obese KK-Ay mice through modulation of small intestinal microbiota signature.

Ryuta Kitagawa1, Kazuyoshi Kon1, Akira Uchiyama1, Kumiko Arai1, Shunhei Yamashina1, Kyoko Kuwahara-Arai2, Teruo Kirikae2, Takashi Ueno3, Kenichi Ikejima1.   

Abstract

Exacerbation of alcoholic hepatitis (AH) with comorbid metabolic syndrome is an emerging clinical problem, where microbiota plays a profound role in the pathogenesis. Here, we investigated the effect of rifaximin (RFX) on liver injury following chronic-binge ethanol (EtOH) administration in KK-Ay mice, a rodent model of metabolic syndrome. Female, 8-wk-old KK-Ay mice were fed Lieber-DeCarli diet (5% EtOH) for 10 days, following a single EtOH gavage (4 g/kg body wt). Some mice were given RFX (0.1 g/L, in liquid diet) orally. Small intestinal contents were collected from mice without binge. Intestinal microbiota was quantified using aerobic and anaerobic culturing techniques and further analyzed by 16S rRNA sequencing in detail. EtOH feeding/binge caused hepatic steatosis, oxidative stress, and induction of inflammatory cytokines in KK-Ay mice, which were markedly prevented by RFX treatment. Hepatic mRNA levels for cluster of differentiation 14, Toll-like receptor (TLR) 4, TLR2, and NADPH oxidase 2 were increased following EtOH feeding/binge, and administration of RFX completely suppressed their increase. The net amount of small intestinal bacteria was increased over threefold after chronic EtOH feeding as expected; however, RFX did not prevent this net increase. Intriguingly, the profile of small intestinal microbiota was dramatically changed following EtOH feeding in the order level, where the Erysipelotrichales predominated in the relative abundance. In sharp contrast, RFX drastically blunted the EtOH-induced increases in the Erysipelotrichales almost completely, with increased proportion of the Bacteroidales. In conclusion, RFX prevents AH through modulation of small intestinal microbiota/innate immune responses in obese KK-Ay mice.NEW & NOTEWORTHY Here we demonstrated that rifaximin (RFX) prevents chronic-binge ethanol (EtOH)-induced steatohepatitis in KK-Ay mice. Chronic EtOH feeding caused small intestinal bacterial overgrowth, with drastic alteration in the microbiota profile predominating the order Erysipelotrichales. RFX minimized this EtOH induction in Erysipelotrichales with substitutive increases in Bacteroidales. RFX also prevented EtOH-induced increases in portal lipopolysaccharide, and hepatic cluster of differentiation 14, toll-like receptor (TLR) 2, and TLR4 mRNA levels, suggesting the potential involvement of microbiota-related innate immune responses.

Entities:  

Keywords:  alcoholic liver disease; dysbiosis; metabolic syndrome; pathogen-associated molecular patterns; toll-like receptor

Mesh:

Substances:

Year:  2019        PMID: 31509430     DOI: 10.1152/ajpgi.00372.2018

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  8 in total

1.  Mitochondrial Side Effects of Surgical Prophylactic Antibiotics Ceftriaxone and Rifaximin Lead to Bowel Mucosal Damage.

Authors:  Bálint Baráth; Dávid K Jász; Tamara Horváth; Bence Baráth; Gergely Maróti; Gerda Strifler; Gabriella Varga; Lilla Sándor; Domonkos Perényi; Szabolcs Tallósy; Tibor Donka; Péter Jávor; Mihály Boros; Petra Hartmann
Journal:  Int J Mol Sci       Date:  2022-05-03       Impact factor: 6.208

2.  Rifaximin Protects against Malathion-Induced Rat Testicular Toxicity: A Possible Clue on Modulating Gut Microbiome and Inhibition of Oxidative Stress by Mitophagy.

Authors:  Nesreen Nabil Omar; Rasha A Mosbah; Wedad S Sarawi; Marwa Medhet Rashed; Amira M Badr
Journal:  Molecules       Date:  2022-06-24       Impact factor: 4.927

Review 3.  Experimental models of metabolic and alcoholic fatty liver disease.

Authors:  Delfin Gerard Buyco; Jasmin Martin; Sookyoung Jeon; Royce Hooks; Chelsea Lin; Rotonya Carr
Journal:  World J Gastroenterol       Date:  2021-01-07       Impact factor: 5.742

4.  Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis.

Authors:  Koji Murata; Kosuke Kaji; Norihisa Nishimura; Masahide Enomoto; Yuki Fujimoto; Soichi Takeda; Yuki Tsuji; Yukihisa Fujinaga; Hiroaki Takaya; Hideto Kawaratani; Tadashi Namisaki; Takemi Akahane; Hitoshi Yoshiji
Journal:  Int J Mol Med       Date:  2022-06-10       Impact factor: 5.314

5.  Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.

Authors:  Yukihisa Fujinaga; Hideto Kawaratani; Daisuke Kaya; Yuki Tsuji; Takahiro Ozutsumi; Masanori Furukawa; Koh Kitagawa; Shinya Sato; Norihisa Nishimura; Yasuhiko Sawada; Hiroaki Takaya; Kosuke Kaji; Naotaka Shimozato; Kei Moriya; Tadashi Namisaki; Takemi Akahane; Akira Mitoro; Hitoshi Yoshiji
Journal:  Int J Mol Sci       Date:  2020-08-04       Impact factor: 5.923

Review 6.  Translational Approaches with Antioxidant Phytochemicals against Alcohol-Mediated Oxidative Stress, Gut Dysbiosis, Intestinal Barrier Dysfunction, and Fatty Liver Disease.

Authors:  Jacob W Ballway; Byoung-Joon Song
Journal:  Antioxidants (Basel)       Date:  2021-03-04

7.  Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity.

Authors:  Yuki Fujimoto; Kosuke Kaji; Norihisa Nishimura; Masahide Enomoto; Koji Murata; Soichi Takeda; Hiroaki Takaya; Hideto Kawaratani; Kei Moriya; Tadashi Namisaki; Takemi Akahane; Hitoshi Yoshiji
Journal:  World J Gastroenterol       Date:  2021-12-28       Impact factor: 5.742

Review 8.  The Use of Rifaximin in Patients With Cirrhosis.

Authors:  Paolo Caraceni; Victor Vargas; Elsa Solà; Carlo Alessandria; Koos de Wit; Jonel Trebicka; Paolo Angeli; Rajeshwar P Mookerjee; François Durand; Elisa Pose; Aleksander Krag; Jasmohan S Bajaj; Ulrich Beuers; Pere Ginès
Journal:  Hepatology       Date:  2021-06-07       Impact factor: 17.425

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.